Sales Through Retail Pharmacies (Twelve months to January 2008*) IMS Retail Drug Monitor covers direct and indirect pharmacy channel purchases from wholesalers and manufacturers in 13 key countries. Sales figures are at ex-manufacturer prices and include all prescription and certain over-the-counter data. Figures include sales from the hospital sector in Japan and mail order in the USA.
NORTH AMERICA $221.7billion up 3%
United States $205.8billion up 3% Canada $15.8billion up 6%
EUROPE (Top 5) $109.5billion up 4%
Germany $32.2billion up 5% France $29.6billion up 4%
United Kingdom $17.4billion up 2% Italy $16.1billion down -2% Spain $13.9billion up 8%
JAPAN (including hospitals) $59.3billion up 5%
LATIN AMERICA (Top 3) $21.9billion up 10%
Brazil $10.6billion up 10% Mexico $8.5billion up 8%
Argentina $2.7billion up 19%
AUSTRALIA/NEW ZEALAND $7.2billion up 10%
The top 5 therapy classes at ATC3 level in the 12 months to January 2008 were:
- C10A – Cholesterol & Triglyceride regulators
- A2B – Antiulcerants
- N6A – Antidepressants & mood stabilisers
- N5A – Antipsychotics 5. N3A – Anti-epileptics T
he top 5 products in the 12 months to January 2008 were:
The top 5 corporations in the 12 months to January 2008 were:
- Merck & Co
*Sales figures here cover direct and indirect pharmaceutical channel purchases (pharmacies plus hospital in Japan and mail order in the USA) from pharmaceutical wholesalers and manufacturers in 13 key global markets. Figures include prescription and certain over-the-counter data, and represent manufacturer prices. These countries account for over two thirds of the world market.
These figures are taken from the monthly pharmaceutical audit conducted by IMS Health, the leading provider of healthcare information worldwide and cover the 12 month period indicated. All sales values are shown in millions of dollars at prevailing exchange rates. In order to remove the effects of fluctuating exchange rates, growth rates are calculated net of exchange, in other words, growth figures are shown at local currency level or constant exchange except for the majority of the Latin America countries exclusive of Mexico, Chile, Colombia and Peru. In Argentina and Brazil sales are recorded in US dollars in Mexico – local currency.
The unique system in Japan reduces the importance of the pharmacy in the distribution chain – sales reported include hospital data. In other countries sales monitored are limited to retail pharmacy only and do not include hospital data. In the USA our survey includes sales through mail order channels. Further details from the Media section of www.imshealth.com.